Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584428 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3587334 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3590952 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3594986 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3589049 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3582718 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3594352 | 0.98 | CSNK1E (0.43) | CSNK1ECNR2ALDH1A1PPARGASAH1 | |
| SCHEMBL3585938 | 0.95 | ALDH1A1 (0.40) | CSNK1ECNR2ALDH1A1KDM4EASAH1 | |
| SCHEMBL158756 | 0.89 | LMNA (0.36) | ALDH1A1KDM4ELMNA | |
| SCHEMBL982653 | 0.84 | NR1I2 (0.37) | CSNK1ECNR2ALDH1A1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121672-B1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-1996546-B1 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN INC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8420628-B2 | Substituted beta-lactams | ALLERGAN, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2041128-B1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8202855-B2 | Substituted beta-lactams | ALLERGAN, INC (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110275692-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-1877050-B1 | SUBSTITUTED BETA-LACTAMS AND THEIR USE IN MEDICINE | ALLERGAN INC (US) | 2011-07-06 | — | — | EP | disclosed |
| US-7973071-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7960381-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7956055-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20070265330-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | OLD DAVID W | 2007-11-15 | — | — | US | disclosed |
| WO-2007109578-A2 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2006121708-A1 | SUBSTITUTED BETA-LACTAMS AND THEIR USE IN MEDICINE | ALLERGAN, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006098918-A2 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004035703-A1 | MELT-FLOW CONTROLLING METHOD FOR ELASTOMER BY UV IRRADIATION | LG CABLE LTD. (KR) | 2004-04-29 | — | — | WO | disclosed |
| US-5025028-A | Asthma | BOEHRINGER MANNHEIM GMBH (DE) | 1991-06-18 | — | — | US | disclosed |
| US-4906666-A | Hydroxamic acids and pharmaceutical compositions containing them, and anti-allergic use thereof | BOEHRINGER MANNHEIM GMBH (DE) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275692-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | CSNK1E 170/4885CNR2 3100/4885ALDH1A1 1580/4885 |
| US-20070265330-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | CSNK1E 170/4885CNR2 3100/4885ALDH1A1 1580/4885 |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | CSNK1E 115/4885CNR2 3368/4885ALDH1A1 1561/4885 |
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | CSNK1E 3523/4885CNR2 449/4885ALDH1A1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.